Marietta, Ohio, Feb. 19, 2020

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders.

“Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage and improved viability when challenged with multiple stressors,” said esteemed biochemist and toxicologist, Dr. Thomas Pulinilkunnil. “This in vitro data supporting the therapeutic utility of PKX-001 is expected to augment the progress of the whole organ and animal studies while screening PKX-001 for inflammatory, hypertrophic and ischemic pathologies in cardiovascular medicine.”

See the promising research of AAGP® and results to date

About ProtoKinetix, Incorporated 

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells, tissues and organs used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.